Effects in The ApoB/ApoA-I Ratio Using Rosuvastatin and Atorvastatin in Patients With Acute Coronary Syndrome
Comparison of the Effects Noted in The ApoB/ApoA-I Ratio Using Rosuvastatin and Atorvastatin in Patients With acUte Coronary Syndrome - CENTAURUS
2 other identifiers
interventional
1,160
10 countries
100
Brief Summary
The purpose of this study is to see if rosuvastatin compared to Atorvastatin is effective in treating ACS by decreasing the ApoB/ApoA-1 ratio and if starting statin within 24 h following the onset of the first symptoms is beneficial compared to placebo.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_3
Started Jan 2006
100 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2006
CompletedFirst Submitted
Initial submission to the registry
February 23, 2006
CompletedFirst Posted
Study publicly available on registry
February 27, 2006
CompletedStudy Completion
Last participant's last visit for all outcomes
October 1, 2007
CompletedDecember 17, 2007
December 1, 2007
February 23, 2006
December 12, 2007
Conditions
Outcome Measures
Primary Outcomes (1)
Percentage changes in ApoB/ApoA-I levels
from Day 0 to 3 months
Secondary Outcomes (3)
Percentage changes in LDL-C
from Day 0 to 1 month and 3 months
Percentage changes in the hs-CRP and AUC of hs-CRP levels
from Day -6 to Day 0
Percentage changes in ApoA-I
from Day 0 to 1 month
Interventions
Eligibility Criteria
You may qualify if:
- Hospital admission for ACS with chest pain or discomfort occurring during rest or with minimal exertion,
- Percutaneous coronary intervention (PCI) planned,
- Evidence of coronary artery disease
You may not qualify if:
- Hypersensitivity to statins
- Any cholesterol lowering medication taken within 1 month prior V1
- Sustained ST-segment elevation on ECG
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- AstraZenecalead
Study Sites (102)
Research Site
Aalst, Belgium
Research Site
Bonheiden, Belgium
Research Site
Bouge, Belgium
Research Site
Brussels, Belgium
Research Site
Charleroi, Belgium
Research Site
Hasselt, Belgium
Research Site
Huy, Belgium
Research Site
La Louvière, Belgium
Research Site
Leuven, Belgium
Research Site
Edmonton, Alberta, Canada
Research Site
Vancouver, British Columbia, Canada
Research Site
Victoria, British Columbia, Canada
Research Site
Winnipeg, Manitoba, Canada
Research Site
Saint John, New Brunswick, Canada
Research Site
St. John's, Newfoundland and Labrador, Canada
Research Site
Halifax, Nova Scotia, Canada
Research Site
Kingston, Ontario, Canada
Research Site
London, Ontario, Canada
Research Site
Scarborough Village, Ontario, Canada
Research Site
Toronto, Ontario, Canada
Research Site
Laval, Quebec, Canada
Research Site
Montreal, Quebec, Canada
Research Site
Pointe-Claire, Quebec, Canada
Research Site
Saint-Charles-Borromée, Quebec, Canada
Research Site
Sherbrooke, Quebec, Canada
Research Site
Regina, Saskatchewan, Canada
Research Site
Tallinn, Estonia
Research Site
Tartu, Estonia
Research Site
Amiens, France
Research Site
Annecy, France
Research Site
Arras, France
Research Site
Avignon, France
Research Site
Boulogne-Billancourt, France
Research Site
Caen, France
Research Site
Cholet, France
Research Site
Créteil, France
Research Site
Dijon, France
Research Site
Eaubonne, France
Research Site
Évecquemont, France
Research Site
Falaise, France
Research Site
La Roche-sur-Yon, France
Research Site
Lagny-sur-Marne, France
Research Site
Le Coudray, France
Research Site
Le Mans, France
Research Site
Lille, France
Research Site
Marseille, France
Research Site
Metz, France
Research Site
Montpellier, France
Research Site
Nevers, France
Research Site
Paris, France
Research Site
Pau, France
Research Site
Pessac, France
Research Site
Reims, France
Research Site
Rouen, France
Research Site
Saint-Herblain, France
Research Site
Suresnes, France
Research Site
Toulouse, France
Research Site
Tourcoing, France
Research Site
Tours, France
Research Site
Valenciennes, France
Research Site
Vannes, France
Research Site
Villeurbanne, France
Research Site
Athens, Greece
Research Site
Balatonfüred, Hungary
Research Site
Budapest, Hungary
Research Site
Pécs, Hungary
Research Site
Zalaegerszeg, Hungary
Research Site
Dublin, Ireland
Research Site
Galway, Ireland
Research Site
Limerick, Ireland
Research Site
Bari, Apulia, Italy
Research site
Cosenza, Basilicate, Italy
Research Site
Benevento, Campania, Italy
Research Site
Mantova, Lombardy, Italy
Research Site
Rozzano (Milano), Lombardy, Italy
Research Site
Catania, Sicily, Italy
Research Site
Pisa, Tuscany, Italy
Research Site
Perugia, Umbria, Italy
Research Site
Verona, Veneto, Italy
Research Site
Bolzano, Italy
Research Site
Napoli, Italy
Research Site
Padua, Italy
Research Site
Roma, Italy
Research Site
Aveiro, Portugal
Research Site
Braga, Portugal
Research Site
Carnaxide, Portugal
Research Site
Faro, Portugal
Research Site
Funchal, Portugal
Research Site
Leiria, Portugal
Research Site
Vila Real, Portugal
Research Site
Zaragoza, Aragon, Spain
Research Site
Toledo, Castille-La Mancha, Spain
Research Site
Tarragona, Catalonia, Spain
Research Site
Fuenlabrada(Madrid), Madrid, Spain
Research site
Madrid, Madrid, Spain
Research Site
Vigo, Pontevedra, Spain
Research Site
Sant Joan d'Alacant, Valencia, Spain
Research Site
Seville, Spain
Research Site
BAB Saâdoun Tunis, Tunisia
Research Site
SIDI Daoud Tunis, Tunisia
Research Site
Sousse, Tunisia
Research Site
Tunis, Tunisia
Related Publications (1)
Lablanche JM, Leone A, Merkely B, Morais J, Alonso J, Santini M, Eha J, Demil N, Licour M, Tardif JC; CENTAURUS investigators. Comparison of the efficacy of rosuvastatin versus atorvastatin in reducing apolipoprotein B/apolipoprotein A-1 ratio in patients with acute coronary syndrome: results of the CENTAURUS study. Arch Cardiovasc Dis. 2010 Mar;103(3):160-9. doi: 10.1016/j.acvd.2010.01.005. Epub 2010 Apr 8.
PMID: 20417447DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
AstraZeneca France Medical Director, MD
AstraZeneca
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
February 23, 2006
First Posted
February 27, 2006
Study Start
January 1, 2006
Study Completion
October 1, 2007
Last Updated
December 17, 2007
Record last verified: 2007-12